3 November 2026
Pfizer beats forecasts and lifts its 2026 outlook as newer drugs pick up the slack
Pfizer's third-quarter profit and revenue topped Wall Street estimates, and it raised full-year guidance even as Covid sales stay low. It also named a longtime insider as CFO.
Pfizer has spent the years since the pandemic trying to prove it is more than a Covid company. Its third-quarter results on Tuesday helped that case: revenue and profit beat forecasts, and the drugmaker raised its full-year outlook thanks to products that have nothing to do with Covid.
What happened
Against analyst estimates compiled by LSEG, Pfizer reported:
- Adjusted earnings per share of 87 cents, versus 73 cents expected. Adjusted means it leaves out items like restructuring charges.
- Revenue of $16.58 billion, versus $15.87 billion expected, roughly flat from a year earlier.
- Net income of $3.24 billion, or 56 cents a share, down from $3.54 billion, or 62 cents a share, a year earlier.
Pfizer now expects 2026 revenue of $62 billion to $64 billion, up from $60.5 billion to $62.5 billion, and adjusted earnings of $2.95 to $3.05 a share, up from $2.80 to $3. That profit forecast absorbs a one-time $650 million charge, booked in the third quarter, tied to a licensing deal with Chinese cancer drugmaker Innovent Biologics. The low end of the new revenue range would still be slightly below 2025's $62.6 billion.
Separately, Cecile Guegan, who has held finance roles at Pfizer for two decades, became chief financial officer this month. She had been interim CFO since August, when Dave Denton left to become CFO of Nike.
Why it matters
The growth came from elsewhere in the medicine cabinet. Blood thinner Eliquis sold $2.52 billion, up 25%, and cancer drug Padcev brought in $720 million, both above forecasts. Pfizer's group of newly launched and acquired products, which includes Padcev, the RSV vaccine Abrysvo and the pneumonia shot Prevnar 20, generated $3.8 billion, up 32% excluding currency effects.
That matters because several of Pfizer's best sellers are approaching the end of their patents, when cheaper generic copies can arrive. CEO Albert Bourla argued Covid has become a much smaller factor, saying the company has shown it can make those sales "irrelevant." Pfizer kept its forecast of about $4 billion of Covid product sales this year, most of it expected in the fourth quarter.
For scale, Noorult's data puts Pfizer's market value at about $175 billion before the results, with roughly $64 billion of revenue and $63 billion of debt on its latest filings. Pfizer is also targeting about $9.7 billion of net cost savings through 2029.
What to watch
- Fourth-quarter Covid vaccine sales during the respiratory season.
- Progress on obesity drugs from Pfizer's purchase of Metsera.
- How fast the newer products grow as older patents expire.
Pfizer's full financials are on its Noorult company page.
The companies in this story
Based on reporting by CNBC: Pfizer hikes full-year outlook on new product growth, taps company veteran as new CFO. Facts, not advice.
More news
- Anthropic's IPO, in numbers: 825 million shares at $70 to $78, and a $1.4 trillion price tag
- Trump says the Nvidia scandal didn't endanger US security, and stands by Lutnick
- Nvidia's first earnings without Huang: what Kress will be asked on Tuesday
- Buffett gives away $5.5 billion of Berkshire stock in his Thanksgiving letter
- Banks are using AI to trim back offices. Proof that it adds revenue is harder to find
- IMF chief says the world economy leans too hard on AI as circular deals top $1 trillion